Skip to main content
OpenTrials
Completed

NCT Number: NCT04353869

Targeting Glutamine Metabolism to Prevent Diabetic Cardiovascular Complications

Experimental data suggest that glutamine catabolism in involved in the activation of macrophages by generating TCA(Tricarboxylic acid) intermediates that promote the pro-inflammatory polarization of macrophages. The project investigates the possible link between glutaminolysis, monocytes polarization and diabetes related cardiovascular complications in humans

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Diabetologie Bichat, Paris, France

Loading trial locations.

About this study

The aim of the study is to investigate the role of glutamine metabolism in the pro-inflammatory activation of macrophages in diabetes and related cardiovascular complications.

The study focuses on 3 adult patients' population with different diabetic status and level of cardiovascular risk:

  • Patients with uncomplicated type 1 or type 2 diabetes and low cardiovascular risk
  • Patients with uncomplicated type 1 or type 2 diabetes and high cardiovascular risk
  • Patients with complicated type 1 or type 2 diabetes

Participants (n=975) will be recruited at clinical sites, in the diabetes and cardiology departments (APHP, Bichat - Claude-Bernard Hospital and APHP, Lariboisière Hospital), over a 2-year period.

The study will consist in a single visit. During a scheduled hospitalization or consultation as part of the follow-up of their diabetes or as part of the follow-up of their cardiological problems, clinical data will be collected as well as additional blood and urine samples for analyses and biobanking. There will be no other intervention specific to the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

General inclusion criteria applying to the five populations are the following:

  • Age above 18 years
  • BMI between 25 and 40 kg/m²

Inclusion criteria

according to study group are listed below.

Group 1: Patients with uncomplicated diabetes and low cardiovascular risk, additional inclusion criteria are:

  • 5 or more years of diabetes
  • 6% < HbA1c < 10%
  • no history of cardiovascular event, diabetic microvascular complications (kidney function normal and albuminuria/creatininuria < 30 mg/g)
  • Coronary artery calcium score < 100 (assessment < 12 months)

Group 2: Patients with uncomplicated diabetes and high cardiovascular risk, additional inclusion criteria are:

  • 5 or more years of diabetes
  • 6% < HbA1c < 10%
  • no history of cardiovascular eventand diabetic nephropathy no more than stage 2 (i.e. GFR ≥ 60 ml/min by MDRD or CKD-EPI formula and albuminuria/creatininuria ≤ 30 mg/g)
  • Coronary artery calcium score > 400 (assessment < 12 months)

Group 3: Patients with complicated diabetes, additional inclusion criteria are:

  • 5 or more years of diabetes
  • 6% < HbA1c < 10%
  • A history of cardiovascular event (myocardial infarction, stroke, peripheral vascular disease, or angioplasty) at least 3 months ago

Exclusion criteria

  • Solid organ or bone marrow transplant patient
  • Pregnant or breastfeeding woman
  • Absence of free and informed consent
  • Non-affiliation to a social security regimen or CMU (universal health coverage)
  • Subject deprived of freedom, subject under a legal protective measure

Treatment and study plan

Bio collection

Biological

venous blood sampling and collection of urine

Primary outcomes

  1. Compare the plasma concentrations of glutamine in patients with various levels of cardiovascular (CV) risk.

    Time frame: DAY 1

    plasma concentration of glutamine in each subject.

Secondary outcomes

  1. Study glutamine metabolism in patients with various levels of CV risk

    Time frame: DAY 1

    plasma concentration of glutamate in each treatment group

  2. Study glutamine metabolism in patients with various levels of CV risk

    Time frame: DAY1

    plasma concentration of a-ketoglutarate, fumarate, and succinate in each treatment group

  3. Study glutamine metabolism in patients with various levels of CV risk

    Time frame: DAY 1

    monocyte cytoplasmic concentration of a-ketoglutarate, fumarate and succinate in each treatment group

  4. study the inflammatory status in patients with various levels of CV risk

    Time frame: DAY 1

    plasma concentration of VEGF (Vascular endothelial growth factor) in each treatment group

  5. study the inflammatory status in patients with various levels of CV risk

    Time frame: DAY 1

    plasma concentration of the proinflammatory cytokines IL-1, IL-6, IL-8 (interleukin) and TNF-a (Tumor Necrosis Factor alpha)

  6. study the inflammatory status in patients with various levels of CV risk

    Time frame: DAY 1

    blood concentration of circulating PBMCs (peripheral blood mononuclear cell)

  7. study the monocyte activation status in patients with various levels of CV risk

    Time frame: DAY 1

    frequency of monocyte subsets (CD14++CD16+, CD14++CD16++, CD14+CD16++)

  8. characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B (Lysine Demethylase 6B) and TET2 (Ten-eleven-translocation 2) activity in blood monocytes from patients with various levels of CV risk

    Time frame: DAY 1

    Number of transcript for each gene

  9. characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B and TET2 activity in blood monocytes from patients with various levels of CV risk

    Time frame: DAY 1

    Number of methylated gene loci and their proportion of methylation

  10. characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B and TET2 activity in blood monocytes from patients with various levels of CV risk

    Time frame: DAY 1

    Frequency and level of histone H3K27me (Methylation of lysine 27 on histone H3) methylation

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • National Research Agency, France

Registry information

Acronym: GLUTADIAB

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Apr 21, 2020
Registry last updated
Mar 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.